Research

Our pursuit of excellent patient care in collaboration with Sarah Cannon Research Institute’s (SCRI) dedication to advancing oncology research provides exceptional cancer care for patients across the United States. ​The two organizations aim to provide people facing cancer with superior, specialized treatment options as well as access to the latest therapies in clinical research close to home.

SCRI is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, McKesson Corporation and HCA Healthcare formed a joint venture combining McKesson’s US Oncology Research and HCA Healthcare’s SCRI to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 750 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively connecting patients to clinical trials at more than 250 locations across the US.

HCA Healthcare Research Institute is the multispecialty clinical research arm of HCA Healthcare committed to advancing care for every individual through our affiliated network of providers and sites. The Research Institute is a connector, bringing together trusted pharmaceutical and biotechnology partners with community-based providers to impact more people in more places.

The Research Institute supports the following therapeutic areas of patient-centered research at more than 40 research sites in 13 divisions:

• Behavioral health
• Cardiac and vascular
• Infectious disease
• Musculoskeletal
• Neuroscience
• Oncology
• Pulmonary and thoracic
• Robotics
• Women and children’s

Over the last decade, the Research Institute has participated in more than 750 industry sponsored studies and worked with more than 250 principal investigators. Our records-based initiatives incorporate data from more than 40 million annual patient encounters. The Research Institute maintains a clinical trial portfolio partnering with more than 175 sponsors of clinical trials. As part of a learning health system, we exist to unlock insights into real-world data and to conduct clinical studies leading to breakthroughs in science, medicine and care for all people.

At HCA Healthcare, research is core to our mission: Above all else, we are committed to the care and improvement of human life.

Children’s Oncology

The Children’s Oncology Group (COG) a member of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN), is the world’s largest organization devoted exclusively to childhood and adolescent cancer research. COG unites over 11,000 experts in childhood cancer at more than 220 leading children’s hospitals, universities, and cancer centers across the United States, Canada, Australia, New Zealand, and Saudi Arabia in the fight against childhood cancer.

Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at COG member institutions. Research performed by COG institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. COG’s mission is to improve the cure rate and outcomes for all children with cancer.

COG has more than 100 active clinical trials open at any given time. There are approximately 12,000 patients registered on COG trials each year. These trials include front-line treatment for many types of childhood cancers, studies aimed at determining the underlying biology of these diseases, and trials involving new and emerging treatments, supportive care, and survivorship.

Additional research partners

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts multi-institutional clinical trials to evaluate promising cellular therapies for patients facing life-threatening disorders. The goal to improve outcomes of therapies such as:

• Hematopoietic cell transplantation (HCT)
• Cellular vaccines
• Chimeric antigen receptor T-cells (CAR-T)

Established in 2001, renewed in 2006, 2011, and 2017, and funded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI), the BMT CTN infrastructure facilitates participation of a large network of centers in trials available to patients in all regions of the United States of America (US).

The BMT CTN:

• Fosters the development of innovative concepts into well-designed trials that can effectively answer important scientific questions
• Supports the timely implementation and completion of trials
• Ensures protection of study participants (both donors and recipients)
• Provides high-quality data in an increasingly complex environment
• Ensures that the rules and regulations and ethical behavior guidelines outlined by federal regulatory bodies are followed
• Promotes timely publication of study results, advancing knowledge and impacting patient care